Bromodomain and extra terminal protein (BET) inhibitors are first-in-class targeted therapies
that deliver a new therapeutic opportunity by directly targeting bromodomain proteins that …

Ibrutinib plus venetoclax is a highly effective combination in mantle cell lymphoma. However,
strategies to enable the evaluation of therapeutic response are required. Our prospective …

People with human immunodeficiency virus (HIV) have higher rates of certain comorbidities,
particularly cardiovascular disease and cancer, than people without HIV 1 , 2 , 3 , 4 – 5 . In …

In the first clinical study to evaluate venetoclax in a solid tumor, we demonstrate that
combining venetoclax with endocrine therapy has a tolerable safety profile and elicits notable …

Purpose Circulating tumor DNA (ctDNA) allows noninvasive disease monitoring across a
range of malignancies. In metastatic melanoma, the extent to which ctDNA reflects changes in …

Targeted therapies against disruptor of telomeric silencing 1-like (DOT1L) and
bromodomain-containing protein 4 (BRD4) are currently being evaluated in clinical trials. However, …

Purpose: Amplification of cyclin E1 (CCNE1) is associated with poor outcome in breast, lung,
and other solid cancers, and is the most prominent structural variant associated with …

High-grade serous cancer (HGSC), the most common subtype of ovarian cancer, often becomes
resistant to chemotherapy, leading to poor patient outcomes. Intratumoral heterogeneity …

Several novel therapeutics are poised to change the natural history of chronic lymphocytic
leukaemia (CLL) and the increasing use of these therapies has highlighted limitations of …

The diagnosis and monitoring of myelodysplastic syndromes (MDSs) are highly reliant on
bone marrow morphology, which is associated with substantial interobserver variability. …